Diabetes has been on the rise for the last few years because of factors such as increased life span of people, hectic lifestyles and increased intake of fatty food. The largest number of cases of diabetes and pre-diabetes are found in the United States, with many still unaware about their diabetes or pre-diabetes condition. It has been estimated that the prevalence of diabetes will be 14% by 2030 in the US. This is likely to put a major burden on healthcare cost of the country. Studies have shown that the total healthcare expenditure in US was US$ 281 Billion in 2014 which was the largest share of the world healthcare expenditure.
The US diabetes care market is segmented into three parts, namely- anti-diabetic drugs segment, insulin delivery devices segment and monitoring and diagnostic devices segment. The most significant growth in the US market has been seen in continuous blood glucose meters, insulin pens, insulin pumps, and anti-diabetic drugs.
The report, “US Diabetes Market Outlook 2020”, highlights the US diabetes market by each segment. The market for each segment has been thoroughly studied and the future market scenario has been forecasted. The prevalence of diabetes and its cost implications have also been indicated in the report. The drivers and challenges of this market have been discussed along with the latest trends and developments. Additionally, information is provided about the key players in this market as well as the steps taken by the government to promote the market. The aforementioned information will help clients in formulating strategies and assessing opportunities in the US diabetes market.
Table of Contents
1. Analyst View
2. Research Methodology
3. Market Overview
4. Patient Profile Analysis
5. Cost Implications
6. Drivers and Challenges
- 6.1. Drivers for Diabetes Market
- 6.1.1. Obesity Leading to Diabetes
- 6.1.2. Rising Disposable Income
- 6.1.3. Increasing Life Span of People
- 6.1.4. Increased Awareness about Diabetes Care
- 6.2. Challenges
- 6.2.1. Traditional Remedies for Diabetes Care
- 6.2.2. High Cost of Anti-diabetic Medication and Diagnostic Devices
- 6.2.3. Long Product Approval Process
7. Diabetes Drugs Market
- 7.1. Oral Anti-Diabetic Drugs Market
- 7.2. Insulin Market
8. Insulin Delivery Devices Market
- 8.1. Insulin Pump
- 8.2. Insulin Pen
- 8.3. Insulin Syringes
- 8.4. Insulin Jet Injectors
- 8.5. Oral Insulin
- 8.6. Inhalable Insulin
9. Glucose Monitoring Devices Market
- 9.1. Glucose Test Strips
- 9.2. Lancets
- 9.3. Blood Glucose Meter
- 9.4. Continuous Blood Glucose Monitors
10. Trends and Developments
- 10.1. Glucose Meters for Easy Detection of Diabetes
- 10.2. Novel Drugs Keep Diabetes in Control
- 10.3. Islet Cell Transplantation- Hope for Diabetes Patients
11. Government Initiatives
12. Competitive Landscape
- 12.1. Drugs
- 12.1.1. Pfizer
- 12.1.2. GlaxoSmithKline
- 12.1.3. Takeda
- 12.1.4. Merck
- 12.2. Insulin Delivery Devices
- 12.2.1. Novo Nordisk
- 12.2.2. Eli Lilly
- 12.2.3. Sanofi
- 12.2.4. Medtronic Inc.
- 12.3. Glucose Monitoring Devices
- 12.3.1. Roche
- 12.3.2. Bayer
- 12.3.3. Abbott Laboratories
List of Figures:
- Figure 3-1: Diabetes Market (Billion US$), 2013 & 2014
- Figure 4-1: Prevalence of Diabetes (%), 2014 & 2030
- Figure 4-2: Number of Diabetic Population (Million), 2014 & 2030
- Figure 5-1: Total Healthcare Expenditure on Diabetes (Billion US$)-US vs. RoW, 2014
- Figure 5-2: Cost per Person (US$) - US vs. RoW for People with Diabetes, 2014
- Figure 6-1: Personal Disposable Income (Billion US$), 2008-2014
- Figure 6-2: Population above 65 Years (Million), 2008-2014
- Figure 7-1: Oral Diabetic Drugs Market (Billion US$), 2014-2020
- Figure 7-2: Insulin Market (Billion US$), 2014-2020
- Figure 7-3: Share of Key Players in Modern Insulin Market (FY 2013)
- Figure 8-1: Insulin Pumps Market (Billion US$), 2014-2020
- Figure 8-2: Shares of Key Players in US Insulin Pump Market (2013)
- Figure 8-3: Insulin Pen Devices Market (Billion US$), 2014-2020
- Figure 8-4: Insulin Syringes Market (Billion US$), 2014-2020
- Figure 8-5: Insulin Jet Injectors Market (Billion US$), 2014-2020
- Figure 9-1: Glucose Test Strips Market (Billion US$), 2014-2020
- Figure 9-2: Lancets Market (Billion US$), 2014-2020
- Figure 9-3: Blood Glucose Meter Market (Billion US$), 2014-2020
- Figure 9-4: Continuous Blood Glucose Monitoring Market (Billion US$), 2014-2020
- Figure 12-1: Pfizer - Breakup of Revenue by Geographies (%), 2014
- Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
- Figure 12-3: Takeda - Breakup of Revenue by Geographies (%), 2014
- Figure 12-4: Merck - Breakup of Revenue by Geographies (%), 2014
- Figure 12-5: Novo Nordisk - Breakup of Revenue by Geographies (%), 2014
- Figure 12-6: Eli Lilly - Breakup of Revenue by Geographies (%), 2014
- Figure 12-7: Sanofi - Breakup of Revenue by Geographies (%), 2014
- Figure 12-8: Medtronic Inc. - Breakup of Revenue by Geographies (%), 2014
- Figure 12-9: Roche - Breakup of Revenue by Geographies (%), 2014
- Figure 12-10: Bayer - Breakup of Revenue by Geographies (%), 2014
- Figure 12-11: Abbott Laboratories - Breakup of Revenue by Geographies (%), 2014
List of Tables:
- Table 4-1: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
- Table 12-1: Pfizer - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-2: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-3: Takeda - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-5: Novo Nordisk - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-6: Eli Lilly - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-7: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-8: Medtronic Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-9: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-10: Bayer - Revenue by Business Segments (Billion US$), 2013 & 2014
- Table 12-11: Abbott Laboratories - Revenue by Business Segments (Billion US$), 2013 & 2014
